CTRI/2024/02/063282
Active, not recruiting
Post Marketing Surveillance
An open label, single-centric, non-randomized clinical study to evaluate the safety and efficacy of a new antimicrobial wound dressing (VELVERT) as an adjuvant therapy in patients having Necrotising soft-tissue infections (NSTI)/ fasciitis
Datt Mediproducts Pvt Ltd,1 site in 1 country20 target enrollmentStarted: February 26, 2024Last updated:
Overview
- Phase
- Post Marketing Surveillance
- Status
- Active, not recruiting
- Sponsor
- Datt Mediproducts Pvt Ltd,
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- A study outcome will be considered if below end points meet.
Overview
Brief Summary
The study enrolled 20 patients with, "Necrotising soft-tissue infections fasciitis" and were treated with an anti-microbial dressing (VELVERT) for a duration of 60 days. Subjects were evaluated at the scheduled visits.
First subject was enrolled on 16-Apr-2024.
Study Design
- Study Type
- Pms
- Allocation
- Na
- Masking
- None
Eligibility Criteria
- Ages
- 18.00 Year(s) to 70.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •Adult male or female subjects within the age group of 18 to 70 years (both inclusive).
- •Subject with HbA1c level below 6.5 % (Well-controlled diabetes mellitus)
- •Subject with soft tissue infection caused by trauma, injury, burn, surgery.
- •Subjects with damaged deep layers of your skin that led to necrosis.
Exclusion Criteria
- •Exclusion Criteria
- •Subject unwilling or unable to comply with the follow up visits necessary for data collection.
- •Subject found positive for HIV, HBsAg and HCV.
- •Concurrent participation in another clinical trial that involves an investigational drug or dressing that would interfere with this study.
- •Pregnant females.
- •Subject with Immunosuppression, corticosteroids or chemotherapy.
- •Subject with decision making impairment.
- •Allergies to any material contained investigational devices.
Outcomes
Primary Outcomes
A study outcome will be considered if below end points meet.
Time Frame: 60 days
• Lesion/wound healed by 60 days (2 months) or prior
Time Frame: 60 days
• Reduction of wound surface area within a time frame of 60 days (2 months). (Change in wound size)
Time Frame: 60 days
Secondary Outcomes
- • Number of patients achieve a complete wound closure or reduction in wound area by ≥ 50% by 60 days or earlier. (Change in wound area).(• Subject self-assessment of intensity of pain. (Pain scale from 0 to 10))
Investigators
Dr Sudhir Kumar
Maharani Laxmi Bai Medical College
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Not Applicable
EFESO: Study on Juvenile Onset Eosinophilic FasciitisNCT07348263Meyer Children's Hospital IRCCS20
Not yet recruiting
Phase 3 4
Evaluation of long term effectiveness of Platelet rich plasma in plantar fasciitisCTRI/2025/02/080861Dr Pragyesh Jain38
Not yet recruiting
Phase 2
A Clinical trial on Lavangapattai Kudineer in the management of Raththa moolam(Bleeding Hemorrhoids) among patients attending OPD and IPD of Government Siddha Medical College and Hospital, Palayamkottai, TirunelveliCTRI/2025/02/080709GOVERNMENT SIDDHA MEDICAL COLLEGE AND HOSPITAL40
Recruiting
Phase 2
ctDNA in HER2+ EBC Neoadjuvant TreatmentNCT07335081Shanghai Jiao Tong University School of Medicine60
Not yet recruiting
Not Applicable
A study to evaluate the efficacy of test regime in lactating females with hair fall.CTRI/2025/07/090485ANVEYA LIVING PRIVATE LIMITED50